[
  {
    "title": "双鹭药业：获磷酸奥司他韦胶囊药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/12/22170637231707.shtml",
    "datetime": "2022-12-22 17:06:47",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：磷酸奥司他韦胶囊获批",
    "href": "http://stock.jrj.com.cn/2022/12/22165937231671.shtml",
    "datetime": "2022-12-22 16:59:28",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：替米沙坦片通过仿制药质量和疗效一致性评价",
    "href": "http://stock.jrj.com.cn/2022/11/21213237155716.shtml",
    "datetime": "2022-11-21 21:32:18",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：董事梁淑洁拟于原减持时间到期后继续减持不超91.91万股",
    "href": "http://stock.jrj.com.cn/2022/11/18183437150834.shtml",
    "datetime": "2022-11-18 18:34:50",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：新乡白鹭拟减持不超1.46%的股份",
    "href": "http://stock.jrj.com.cn/2022/11/07181137117821.shtml",
    "datetime": "2022-11-07 18:11:15",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：阿加曲班注射液获批上市",
    "href": "http://stock.jrj.com.cn/2022/11/07180937117776.shtml",
    "datetime": "2022-11-07 18:09:45",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)第三季度净利7262.09万元 同比下降45.97%",
    "href": "http://stock.jrj.com.cn/2022/10/25180837082401.shtml",
    "datetime": "2022-10-25 18:08:29",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股公司星昊医药于北交所的上市申请通过上市委审议",
    "href": "http://stock.jrj.com.cn/2022/10/13165637053111.shtml",
    "datetime": "2022-10-13 16:56:52",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：高管梁淑洁减持期过半未减持",
    "href": "http://stock.jrj.com.cn/2022/09/08174036983799.shtml",
    "datetime": "2022-09-08 17:40:40",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)半年度净利润1.65亿元 同比下降45.17%",
    "href": "http://stock.jrj.com.cn/2022/08/23180836927008.shtml",
    "datetime": "2022-08-23 18:08:17",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：2021年度权益分派10派1元 股权登记日6月28日",
    "href": "http://stock.jrj.com.cn/2022/06/21171936746684.shtml",
    "datetime": "2022-06-21 17:19:26",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：伏立康唑片获得药品注册证书",
    "href": "http://stock.jrj.com.cn/2022/05/26180236681837.shtml",
    "datetime": "2022-05-26 18:02:56",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：董事梁淑洁拟减持不超52.50万股",
    "href": "http://stock.jrj.com.cn/2022/05/13185236647499.shtml",
    "datetime": "2022-05-13 18:52:41",
    "code": "002038"
  },
  {
    "title": "快讯：双鹭药业急速拉升5.47% 主力资金净流入2617.56万元(dev)",
    "href": "http://stock.jrj.com.cn/2022/05/09104136603752.shtml",
    "datetime": "2022-05-09 10:41:02",
    "code": "002038"
  },
  {
    "title": "双鹭药业2022年第一季度净利6329.59万同比下滑31.07% 公允价值变动收益下降",
    "href": "http://stock.jrj.com.cn/2022/05/03171136544859.shtml",
    "datetime": "2022-05-03 17:11:41",
    "code": "002038"
  },
  {
    "title": "双鹭药业2021年净利4.26亿同比增长16.79% 董事长徐明波薪酬35万",
    "href": "http://stock.jrj.com.cn/2022/04/26223136479141.shtml",
    "datetime": "2022-04-26 22:31:09",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股公司首药控股于科创板IPO获证监会同意注册",
    "href": "http://stock.jrj.com.cn/2022/02/09160034313430.shtml",
    "datetime": "2022-02-09 16:00:50",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：创新药DT678片获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/12/07163933980339.shtml",
    "datetime": "2021-12-07 16:39:40",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：长效重组人胰高血糖素样肽-1注射液获批临床试验",
    "href": "http://stock.jrj.com.cn/2021/11/05163333817099.shtml",
    "datetime": "2021-11-05 16:33:55",
    "code": "002038"
  },
  {
    "title": "双鹭药业2021年半年度净利3.02亿元 同比净利增加53.24%",
    "href": "http://stock.jrj.com.cn/2021/08/26171433324920.shtml",
    "datetime": "2021-08-26 17:14:45",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：奥硝唑注射液(遁宁)通过一致性评价",
    "href": "http://stock.jrj.com.cn/2021/08/05155633206873.shtml",
    "datetime": "2021-08-05 15:56:40",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股的首药控股于科创板IPO通过上市委审议",
    "href": "http://stock.jrj.com.cn/2021/08/03193633197320.shtml",
    "datetime": "2021-08-03 19:36:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：第二大股东因可交债换股被动减持1055.026万股",
    "href": "http://stock.jrj.com.cn/2021/06/29155933015851.shtml",
    "datetime": "2021-06-29 15:59:28",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)2020年度权益分派10派1元 股权登记日为7月6日",
    "href": "http://stock.jrj.com.cn/2021/06/28192933011456.shtml",
    "datetime": "2021-06-28 19:29:15",
    "code": "002038"
  },
  {
    "title": "双鹭药业：欧美专利保护到2022-2024年目前难以突破",
    "href": "http://stock.jrj.com.cn/2021/05/10191032731248.shtml",
    "datetime": "2021-05-10 19:10:41",
    "code": "002038"
  },
  {
    "title": "双鹭药业：目前公司第二大股东修改后的转股价格为9.45元/股",
    "href": "http://stock.jrj.com.cn/2021/05/10190832731241.shtml",
    "datetime": "2021-05-10 19:08:11",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2020年报里提到的3家参股公司年内IPO系指首药控股、长风药业和星昊医药",
    "href": "http://stock.jrj.com.cn/2021/05/10173432730485.shtml",
    "datetime": "2021-05-10 17:34:39",
    "code": "002038"
  },
  {
    "title": "双鹭药业：用于治疗阿尔兹海默症的泰思胶目前该项目仍在III期临床阶段",
    "href": "http://stock.jrj.com.cn/2021/05/10172632730442.shtml",
    "datetime": "2021-05-10 17:26:46",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司不存在研发费用集中在第四季度计算的情况",
    "href": "http://stock.jrj.com.cn/2021/05/10172532730441.shtml",
    "datetime": "2021-05-10 17:25:58",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司2020年第三季度营业收入3.05亿元人民币",
    "href": "http://stock.jrj.com.cn/2021/05/10172532730439.shtml",
    "datetime": "2021-05-10 17:25:26",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司申请的沟通交流会系申报正常环节",
    "href": "http://stock.jrj.com.cn/2021/05/10172532730438.shtml",
    "datetime": "2021-05-10 17:25:19",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：第二大股东新乡白鹭持股降至18.02%",
    "href": "http://stock.jrj.com.cn/2021/05/06171032701945.shtml",
    "datetime": "2021-05-06 17:10:06",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：获得利伐沙班片药品注册证书",
    "href": "http://stock.jrj.com.cn/2021/05/05190532680579.shtml",
    "datetime": "2021-05-05 19:05:55",
    "code": "002038"
  },
  {
    "title": "双鹭药业：产品已完成临床前研究并提交临床沟通交流会申请",
    "href": "http://stock.jrj.com.cn/2021/04/30191432488809.shtml",
    "datetime": "2021-04-30 19:14:43",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司投资首药控股系看好其未来发展潜力",
    "href": "http://stock.jrj.com.cn/2021/04/30191232488787.shtml",
    "datetime": "2021-04-30 19:12:46",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司胸腺五肽粉针在广西集中招标采购中已中标",
    "href": "http://stock.jrj.com.cn/2021/04/30190732488757.shtml",
    "datetime": "2021-04-30 19:07:38",
    "code": "002038"
  },
  {
    "title": "双鹭药业：集中招标采购按季度下达集采定单 而非一次采购一年的量",
    "href": "http://stock.jrj.com.cn/2021/04/30190732488761.shtml",
    "datetime": "2021-04-30 19:07:28",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司已进入多产品支撑主业业绩、多渠道贡献利润的局面",
    "href": "http://stock.jrj.com.cn/2021/04/30160632487437.shtml",
    "datetime": "2021-04-30 16:06:44",
    "code": "002038"
  },
  {
    "title": "双鹭药业：目前公司参股康明百奥的股权正在与轩竹生物恰谈",
    "href": "http://stock.jrj.com.cn/2021/04/12155532357962.shtml",
    "datetime": "2021-04-12 15:55:20",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：参股公司首药控股科创板IPO申请获上交所受理",
    "href": "http://stock.jrj.com.cn/2021/03/17115032150298.shtml",
    "datetime": "2021-03-17 11:50:18",
    "code": "002038"
  },
  {
    "title": "双鹭药业：如果替莫唑胺集采影响提前到一季度会带来一季度业绩的快速增长",
    "href": "http://stock.jrj.com.cn/2021/03/03180932064697.shtml",
    "datetime": "2021-03-03 18:09:09",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司排名第一和第二的产品同时被调出地方医保 故去年对公司造成较大的影响",
    "href": "http://stock.jrj.com.cn/2021/03/03180232064634.shtml",
    "datetime": "2021-03-03 18:02:30",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司参股公司蒙博润与海布生物均涉足医美和大健康领域",
    "href": "http://stock.jrj.com.cn/2021/03/03175832064636.shtml",
    "datetime": "2021-03-03 17:58:45",
    "code": "002038"
  },
  {
    "title": "双鹭药业：按照招标采购报量 今年替莫唑胺有望增长数倍",
    "href": "http://stock.jrj.com.cn/2021/03/03175532064547.shtml",
    "datetime": "2021-03-03 17:55:59",
    "code": "002038"
  },
  {
    "title": "双鹭药业：医美项目只是公司参股和控股公司涉及 他们条件成熟时会考虑上市",
    "href": "http://stock.jrj.com.cn/2021/03/03175432064536.shtml",
    "datetime": "2021-03-03 17:54:49",
    "code": "002038"
  },
  {
    "title": "双鹭药业：长效重组人胰高血糖素样肽-1注射液项目需要进行补充研究后再行提交",
    "href": "http://stock.jrj.com.cn/2021/03/03171732064295.shtml",
    "datetime": "2021-03-03 17:17:24",
    "code": "002038"
  },
  {
    "title": "双鹭药业：美国吉卡宾项目处暂停阶段 主要是在安全性及调整适应症方面做进一步补充数据",
    "href": "http://stock.jrj.com.cn/2021/03/03171632064296.shtml",
    "datetime": "2021-03-03 17:16:22",
    "code": "002038"
  },
  {
    "title": "双鹭药业2020年度净利3.56亿下滑26.78% 投资收益增加",
    "href": "http://stock.jrj.com.cn/2021/02/26180932034167.shtml",
    "datetime": "2021-02-26 18:09:32",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)业绩快报：2020年净利降26.78%至3.56亿元",
    "href": "http://stock.jrj.com.cn/2021/02/26163532033339.shtml",
    "datetime": "2021-02-26 16:35:11",
    "code": "002038"
  },
  {
    "title": "双鹭药业：我们有信心自今年一季度始让公司重回业绩增长之路",
    "href": "http://stock.jrj.com.cn/2021/02/18175831987579.shtml",
    "datetime": "2021-02-18 17:58:24",
    "code": "002038"
  },
  {
    "title": "双鹭药业：集采对公司而言有些产品将带来很好的市场机会，我们将努力抓住这些机会",
    "href": "http://stock.jrj.com.cn/2021/02/18175731987548.shtml",
    "datetime": "2021-02-18 17:57:27",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司股价下降影响了所有股东的利益而不仅是小股东的利益",
    "href": "http://stock.jrj.com.cn/2021/02/18175431987540.shtml",
    "datetime": "2021-02-18 17:54:57",
    "code": "002038"
  },
  {
    "title": "双鹭药业：立争公司再回业绩稳健增长之路",
    "href": "http://stock.jrj.com.cn/2021/02/18175431987538.shtml",
    "datetime": "2021-02-18 17:54:56",
    "code": "002038"
  },
  {
    "title": "双鹭药业董事长兼总经理徐明波增持31.5万股 耗资约289.8万元",
    "href": "http://stock.jrj.com.cn/2021/01/13214931686492.shtml",
    "datetime": "2021-01-13 21:49:13",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)获董事长徐明波增持31.5万股",
    "href": "http://stock.jrj.com.cn/2021/01/13181431685424.shtml",
    "datetime": "2021-01-13 18:14:27",
    "code": "002038"
  },
  {
    "title": "双鹭药业第二大股东新乡白鹭质押600万股 用于发行可交换公司债券补充质押",
    "href": "http://stock.jrj.com.cn/2021/01/08201731657365.shtml",
    "datetime": "2021-01-08 20:17:44",
    "code": "002038"
  },
  {
    "title": "双鹭药业：拟2100万元参与增资新乡双鹭 进一步加强其原料药基地建设",
    "href": "http://stock.jrj.com.cn/2021/01/08195531657543.shtml",
    "datetime": "2021-01-08 19:55:46",
    "code": "002038"
  },
  {
    "title": "新乡化纤(000949.SZ)：与双鹭药业拟按持股比例共同对新乡双鹭增资3000万元",
    "href": "http://stock.jrj.com.cn/2021/01/08180831656566.shtml",
    "datetime": "2021-01-08 18:08:07",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)：第二大股东质押600万股",
    "href": "http://stock.jrj.com.cn/2021/01/08175731656458.shtml",
    "datetime": "2021-01-08 17:57:12",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司培门冬酶注射液研发项目还处于临床研究阶段",
    "href": "http://stock.jrj.com.cn/2021/01/07175731648991.shtml",
    "datetime": "2021-01-07 17:57:56",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司2020年多个品种获批生产/临床 大部分研发项目均在有序进行中",
    "href": "http://stock.jrj.com.cn/2021/01/07175131648953.shtml",
    "datetime": "2021-01-07 17:51:15",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]特惠活动继续进行中",
    "href": "http://stock.jrj.com.cn/2020/12/07000031436727.shtml",
    "datetime": "2020-12-07 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]股东福利来了",
    "href": "http://stock.jrj.com.cn/2020/12/07000031436726.shtml",
    "datetime": "2020-12-07 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：与美国公司合作的项目进展尚需结合美国公司的进展情况",
    "href": "http://stock.jrj.com.cn/2020/12/04184831409786.shtml",
    "datetime": "2020-12-04 18:48:10",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司在心脑血管、血液病、肿瘤等领域也培育了多个潜力品种并形成系列",
    "href": "http://stock.jrj.com.cn/2020/12/04184631409785.shtml",
    "datetime": "2020-12-04 18:46:28",
    "code": "002038"
  },
  {
    "title": "双鹭药业：积极应对两票制和集采后市场的变化",
    "href": "http://stock.jrj.com.cn/2020/12/04180431409496.shtml",
    "datetime": "2020-12-04 18:04:43",
    "code": "002038"
  },
  {
    "title": "双鹭药业：公司替莫唑胺胶囊100mg 获批上市",
    "href": "http://stock.jrj.com.cn/2020/12/04180031409431.shtml",
    "datetime": "2020-12-04 18:00:41",
    "code": "002038"
  },
  {
    "title": "双鹭药业2020年前三季度净利3.03亿下滑39.72% 销售订单减少",
    "href": "http://stock.jrj.com.cn/2020/11/01124531183423.shtml",
    "datetime": "2020-11-01 12:45:08",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司替莫唑胺胶囊(20mg)通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/09/25000030834744.shtml",
    "datetime": "2020-09-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司获得利拉鲁肽注射液临床试验通知书",
    "href": "http://stock.jrj.com.cn/2020/09/25000030834743.shtml",
    "datetime": "2020-09-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司获得替莫唑胺胶囊(100mg)药品注册证书且视同通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/09/25000030834742.shtml",
    "datetime": "2020-09-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]控股子公司海布生物科技(云南)有限公司通过“国产非特殊用途化妆品备案”",
    "href": "http://stock.jrj.com.cn/2020/09/25000030834745.shtml",
    "datetime": "2020-09-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司获得 3 类新药富马酸替诺福韦二吡呋酯片(0.15g, 0.2g)药品注册证书",
    "href": "http://stock.jrj.com.cn/2020/09/25000030834747.shtml",
    "datetime": "2020-09-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业(002038.SZ)逆势收涨4.09% 含CBD国产非特殊用途化妆品备案获通过",
    "href": "http://stock.jrj.com.cn/2020/09/09150330711604.shtml",
    "datetime": "2020-09-09 15:03:20",
    "code": "002038"
  },
  {
    "title": "双鹭药业替莫唑胺胶囊（20mg）通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/09/08182230705251.shtml",
    "datetime": "2020-09-08 18:22:18",
    "code": "002038"
  },
  {
    "title": "【公告抢先看】晚间重要公告：双鹭药业含大麻叶提取物CBD的国产非特殊用途化妆品备案获通过……",
    "href": "http://stock.jrj.com.cn/2020/09/08181330705184.shtml",
    "datetime": "2020-09-08 18:13:27",
    "code": "002038"
  },
  {
    "title": "双鹭药业：含大麻叶提取物CBD的国产非特殊用途化妆品备案获得审批通过",
    "href": "http://stock.jrj.com.cn/2020/09/08165330704563.shtml",
    "datetime": "2020-09-08 16:53:35",
    "code": "002038"
  },
  {
    "title": "双鹭药业获得替莫唑胺胶囊（100mg）药品注册证书",
    "href": "http://stock.jrj.com.cn/2020/08/31170230644218.shtml",
    "datetime": "2020-08-31 17:02:47",
    "code": "002038"
  },
  {
    "title": "双鹭药业获得富马酸替诺福韦二吡呋酯片药品注册证书",
    "href": "http://stock.jrj.com.cn/2020/08/20195430551348.shtml",
    "datetime": "2020-08-20 19:54:55",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]双鹭药业立生?(来那度胺胶囊)通过一致性评价",
    "href": "http://stock.jrj.com.cn/2020/06/30000030102241.shtml",
    "datetime": "2020-06-30 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司注射用丁二磺酸腺苷蛋氨酸已获批生产",
    "href": "http://stock.jrj.com.cn/2020/06/29000030087392.shtml",
    "datetime": "2020-06-29 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：注射用丁二磺酸腺苷蛋氨酸获得药品注册批件",
    "href": "http://stock.jrj.com.cn/2020/06/19182129968097.shtml",
    "datetime": "2020-06-19 18:21:40",
    "code": "002038"
  },
  {
    "title": "双鹭药业：注射用丁二磺酸腺苷蛋氨酸获得“药品注册批件”",
    "href": "http://stock.jrj.com.cn/2020/06/19155929966741.shtml",
    "datetime": "2020-06-19 15:59:28",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]双鹭药业以双鹭讲堂方式加强内部技术人员培训",
    "href": "http://stock.jrj.com.cn/2020/06/19000029981048.shtml",
    "datetime": "2020-06-19 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业股东新乡白鹭质押400万股 用于补充质押",
    "href": "http://stock.jrj.com.cn/2020/05/22215629742671.shtml",
    "datetime": "2020-05-22 21:56:01",
    "code": "002038"
  },
  {
    "title": "双鹭药业2020年第一季度盈利6158.28万元 下降69.29% 医保政策和疫情影响",
    "href": "http://stock.jrj.com.cn/2020/05/03110829492977.shtml",
    "datetime": "2020-05-03 11:08:56",
    "code": "002038"
  },
  {
    "title": "双鹭药业2019年净利4.86亿元 同比减少14.82% 研发费用增加",
    "href": "http://stock.jrj.com.cn/2020/04/30185229433968.shtml",
    "datetime": "2020-04-30 18:52:06",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2020年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/04/15080029292335.shtml",
    "datetime": "2020-04-15 08:00:30",
    "code": "002038"
  },
  {
    "title": "双鹭药业股东新乡白鹭质押300万股 用于补充质押",
    "href": "http://stock.jrj.com.cn/2020/04/07181329227219.shtml",
    "datetime": "2020-04-07 18:13:43",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]北京蒙博润生物科技有限公司获得消毒产品生产企业卫生许可证",
    "href": "http://stock.jrj.com.cn/2020/03/06000029890657.shtml",
    "datetime": "2020-03-06 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业2019年净利润5.1亿元减少11% 销售费用增加",
    "href": "http://stock.jrj.com.cn/2020/02/27211328908930.shtml",
    "datetime": "2020-02-27 21:13:49",
    "code": "002038"
  },
  {
    "title": "双鹭药业：第二批捐赠救援药品发往武汉",
    "href": "http://stock.jrj.com.cn/2020/02/12130728814986.shtml",
    "datetime": "2020-02-12 13:07:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]欣吉尔与欧宁助您免疫力快速提升!",
    "href": "http://stock.jrj.com.cn/2020/02/09000029890660.shtml",
    "datetime": "2020-02-09 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司利巴韦林列入第五版新冠肺炎诊疗方案",
    "href": "http://stock.jrj.com.cn/2020/02/09000029890656.shtml",
    "datetime": "2020-02-09 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]抗击新冠肺炎,双鹭药业在行动",
    "href": "http://stock.jrj.com.cn/2020/01/28000029890653.shtml",
    "datetime": "2020-01-28 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业全资子公司双鹭生物获得《高新技术企业证书》",
    "href": "http://stock.jrj.com.cn/2020/01/07195928638805.shtml",
    "datetime": "2020-01-07 19:59:37",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]双鹭药业隆重举办公司25周年庆典暨2020年迎春晚会",
    "href": "http://stock.jrj.com.cn/2019/12/25000029890661.shtml",
    "datetime": "2019-12-25 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]我公司“遁宁奥硝唑注射液”获“最具市场竞争力新锐品种(抗感染用药)”",
    "href": "http://stock.jrj.com.cn/2019/12/06000029890654.shtml",
    "datetime": "2019-12-06 00:00:00",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]双鹭药业新型白介素-2为系统性红斑狼疮患者带来福音",
    "href": "http://stock.jrj.com.cn/2019/11/01000029890651.shtml",
    "datetime": "2019-11-01 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业第三季度盈利1.46亿 同比下滑19.58%",
    "href": "http://stock.jrj.com.cn/2019/10/27215628305892.shtml",
    "datetime": "2019-10-27 21:56:58",
    "code": "002038"
  },
  {
    "title": "[双鹭药业]双鹭药业获美国GEMP公司降脂新药中国市场独家开发权",
    "href": "http://stock.jrj.com.cn/2019/10/16000029890652.shtml",
    "datetime": "2019-10-16 00:00:00",
    "code": "002038"
  },
  {
    "title": "独家药品受冲击，双鹭药业看上了治“不孕不育”这门生意",
    "href": "http://stock.jrj.com.cn/2019/10/10005628224044.shtml",
    "datetime": "2019-10-10 00:56:03",
    "code": "002038"
  },
  {
    "title": "双鹭药业：获注射用重组人促卵泡激素临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/10/09202928223405.shtml",
    "datetime": "2019-10-09 20:29:21",
    "code": "002038"
  },
  {
    "title": "双鹭药业：获得注射用重组人促卵泡激素临床试验通知书",
    "href": "http://stock.jrj.com.cn/2019/10/09192728223234.shtml",
    "datetime": "2019-10-09 19:27:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业2019年上半年净利3.57亿 依诺肝素钠等销量稳步增长",
    "href": "http://stock.jrj.com.cn/2019/08/26211228035701.shtml",
    "datetime": "2019-08-26 21:12:58",
    "code": "002038"
  },
  {
    "title": "双鹭药业的来那度胺之战：江湖混战 国产化尝试",
    "href": "http://stock.jrj.com.cn/2019/07/21141027866787.shtml",
    "datetime": "2019-07-21 14:10:24",
    "code": "002038"
  },
  {
    "title": "双鹭药业收入支柱遭政策打压 重要产品深陷价格困局",
    "href": "http://stock.jrj.com.cn/2019/07/13101627836276.shtml",
    "datetime": "2019-07-13 10:16:52",
    "code": "002038"
  },
  {
    "title": "双鹭药业收入支柱遭政策打压 重要产品深陷价格战困局",
    "href": "http://stock.jrj.com.cn/2019/07/13093127836213.shtml",
    "datetime": "2019-07-13 09:31:46",
    "code": "002038"
  },
  {
    "title": "双鹭药业：不存在长期不回复投资者问题 但重复问题处理欠妥",
    "href": "http://stock.jrj.com.cn/2019/07/04121727796341.shtml",
    "datetime": "2019-07-04 12:17:49",
    "code": "002038"
  },
  {
    "title": "双鹭药业股东徐明波增持11万股 增持耗资232万元",
    "href": "http://stock.jrj.com.cn/2019/06/12190627695570.shtml",
    "datetime": "2019-06-12 19:06:05",
    "code": "002038"
  },
  {
    "title": "双鹭药业：董事长增持11万股",
    "href": "http://stock.jrj.com.cn/2019/06/12120427693742.shtml",
    "datetime": "2019-06-12 12:04:27",
    "code": "002038"
  },
  {
    "title": "午间公告集锦：双鹭药业董事长增持公司股份",
    "href": "http://stock.jrj.com.cn/2019/06/12115927693717.shtml",
    "datetime": "2019-06-12 11:59:07",
    "code": "002038"
  },
  {
    "title": "午间公告：双鹭药业董事长增持公司股份",
    "href": "http://stock.jrj.com.cn/2019/06/12115927693737.shtml",
    "datetime": "2019-06-12 11:59:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业 2019年第一季度净利2亿元 财务负责人席文英持有公司股份49万股",
    "href": "http://stock.jrj.com.cn/2019/04/24154127474649.shtml",
    "datetime": "2019-04-24 15:41:23",
    "code": "002038"
  },
  {
    "title": "双鹭药业去年净利5.7亿元 同比增长7% 董事长徐明波薪酬39万元",
    "href": "http://stock.jrj.com.cn/2019/04/23214227469048.shtml",
    "datetime": "2019-04-23 21:42:11",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年年度报告主要财务指标及分配预案",
    "href": "http://stock.jrj.com.cn/2019/04/23195027468365.shtml",
    "datetime": "2019-04-23 19:50:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年净利同比增7.1% 拟10送5派3元",
    "href": "http://stock.jrj.com.cn/2019/04/23183727467860.shtml",
    "datetime": "2019-04-23 18:37:07",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年净利增7.1% 拟10送5派3",
    "href": "http://stock.jrj.com.cn/2019/04/23171027467142.shtml",
    "datetime": "2019-04-23 17:10:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年净利同比增长7% 拟10送5派3元",
    "href": "http://stock.jrj.com.cn/2019/04/23170127467089.shtml",
    "datetime": "2019-04-23 17:01:32",
    "code": "002038"
  },
  {
    "title": "双鹭药业股东新乡白鹭减持280万股 套现约7913万元",
    "href": "http://stock.jrj.com.cn/2019/03/19080527189359.shtml",
    "datetime": "2019-03-19 08:05:55",
    "code": "002038"
  },
  {
    "title": "双鹭药业子公司申请新三板摘牌 主营体外诊断",
    "href": "http://stock.jrj.com.cn/2019/03/14191027167920.shtml",
    "datetime": "2019-03-14 19:10:50",
    "code": "002038"
  },
  {
    "title": "双鹭药业炒股亏损 下修2018年利润约1亿元",
    "href": "http://stock.jrj.com.cn/2019/01/31185227009142.shtml",
    "datetime": "2019-01-31 18:52:02",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年年度业绩报告预告(修正公告)",
    "href": "http://stock.jrj.com.cn/2019/01/31184027009051.shtml",
    "datetime": "2019-01-31 18:40:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业第二大股东拟减持不超过280万股 占比0.41%",
    "href": "http://stock.jrj.com.cn/2019/01/24182326952797.shtml",
    "datetime": "2019-01-24 18:23:21",
    "code": "002038"
  },
  {
    "title": "双鹭药业：前三季净利5.32亿元 同比增长36%",
    "href": "http://stock.jrj.com.cn/hotstock/2018/10/30080025277220.shtml",
    "datetime": "2018-10-30 08:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/10/29183025273415.shtml",
    "datetime": "2018-10-29 18:30:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：七、八月份销售形势好于上半年",
    "href": "http://stock.jrj.com.cn/2018/09/13103525087343.shtml",
    "datetime": "2018-09-13 10:35:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：上半年净利3.5亿 同比增长50%",
    "href": "http://stock.jrj.com.cn/hotstock/2018/08/29080025017646.shtml",
    "datetime": "2018-08-29 08:00:02",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年前三季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/08/28181025014897.shtml",
    "datetime": "2018-08-28 18:10:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：上半年净利3.5亿 同比增50%",
    "href": "http://stock.jrj.com.cn/2018/08/28173525014641.shtml",
    "datetime": "2018-08-28 17:35:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业上半年净利润同比增五成",
    "href": "http://stock.jrj.com.cn/2018/08/28163525014388.shtml",
    "datetime": "2018-08-28 16:35:13",
    "code": "002038"
  },
  {
    "title": "双鹭药业：二股东拟减持不超800万股",
    "href": "http://stock.jrj.com.cn/2018/06/01202524627547.shtml",
    "datetime": "2018-06-01 20:25:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业获得长效重组人促卵泡激素注射液药物临床试验批件",
    "href": "http://stock.jrj.com.cn/2018/06/01201324627531.shtml",
    "datetime": "2018-06-01 20:13:29",
    "code": "002038"
  },
  {
    "title": "双鹭药业：重组全人抗CTLA-4单克隆抗体注射液药物临床试验批件",
    "href": "http://stock.jrj.com.cn/hotstock/2018/05/25075924588819.shtml",
    "datetime": "2018-05-25 07:59:58",
    "code": "002038"
  },
  {
    "title": "双鹭药业：2018年第一季度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2018/03/29165024322621.shtml",
    "datetime": "2018-03-29 16:50:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：设立北京双鹭公益慈善基金会",
    "href": "http://stock.jrj.com.cn/hotstock/2018/03/20080024264668.shtml",
    "datetime": "2018-03-20 08:00:02",
    "code": "002038"
  },
  {
    "title": "双鹭药业称来那度胺销售权事宜存分歧",
    "href": "http://stock.jrj.com.cn/2018/01/11053923927773.shtml",
    "datetime": "2018-01-11 05:39:32",
    "code": "002038"
  },
  {
    "title": "双鹭药业与卡文迪许各执一词 重磅新药来那度胺陷销售权纷争",
    "href": "http://stock.jrj.com.cn/2018/01/09074823916070.shtml",
    "datetime": "2018-01-09 07:48:00",
    "code": "002038"
  },
  {
    "title": "[哈药股份]“一买一卖”再启海外投资 双鹭药业的逻辑是什么",
    "href": "http://stock.jrj.com.cn/2017/12/27000023861152.shtml",
    "datetime": "2017-12-27 00:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：拟转让华润普仁鸿20%股权 将产生1.2",
    "href": "http://stock.jrj.com.cn/hotstock/2017/12/19080023813948.shtml",
    "datetime": "2017-12-19 08:00:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：拟转让华润普仁鸿20%股权 将产生1.21亿元投资收益",
    "href": "http://stock.jrj.com.cn/2017/12/18184023811825.shtml",
    "datetime": "2017-12-18 18:40:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：子公司获准在新三板挂牌 利好短线股价",
    "href": "http://stock.jrj.com.cn/2016/12/01172421781212.shtml",
    "datetime": "2016-12-01 17:24:48",
    "code": "002038"
  },
  {
    "title": "双鹭药业重磅药有望获批 引发亿万资金建仓豪赌",
    "href": "http://stock.jrj.com.cn/hotstock/2016/06/12164221056885.shtml",
    "datetime": "2016-06-12 16:42:00",
    "code": "002038"
  },
  {
    "title": "激辩达沙替尼：双鹭药业、正大天晴首仿争议",
    "href": "http://stock.jrj.com.cn/2014/07/30024017702190.shtml",
    "datetime": "2014-07-30 02:40:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业抛亿元回购计划",
    "href": "http://stock.jrj.com.cn/2014/06/05024017342872.shtml",
    "datetime": "2014-06-05 02:40:39",
    "code": "002038"
  },
  {
    "title": "招商证券：双鹭药业 新品提升估值",
    "href": "http://stock.jrj.com.cn/hotstock/2013/08/19140415705803.shtml",
    "datetime": "2013-08-19 14:04:27",
    "code": "002038"
  },
  {
    "title": "双鹭药业：有望进入新的加速发展阶段",
    "href": "http://stock.jrj.com.cn/hotstock/2013/04/18131715239016.shtml",
    "datetime": "2013-04-18 13:17:10",
    "code": "002038"
  },
  {
    "title": "双鹭药业新药研发进入收获期",
    "href": "http://stock.jrj.com.cn/2013/04/10150915215843.shtml",
    "datetime": "2013-04-10 15:09:14",
    "code": "002038"
  },
  {
    "title": "双鹭药业多品种入选2012版基药目录",
    "href": "http://stock.jrj.com.cn/2013/03/19160515155535.shtml",
    "datetime": "2013-03-19 16:05:09",
    "code": "002038"
  },
  {
    "title": "双鹭药业：短期无忧 长期关注在研品种实质进展",
    "href": "http://stock.jrj.com.cn/hotstock/2012/11/23150514723234.shtml",
    "datetime": "2012-11-23 15:05:29",
    "code": "002038"
  },
  {
    "title": "双鹭药业:业绩符合预期 多点开花推动未来增长",
    "href": "http://stock.jrj.com.cn/hotstock/2012/07/20123913865684.shtml",
    "datetime": "2012-07-20 12:39:59",
    "code": "002038"
  },
  {
    "title": "双鹭药业上半年净利2.22亿元 同比下降36%",
    "href": "http://stock.jrj.com.cn/2012/07/19203913853124.shtml",
    "datetime": "2012-07-19 20:39:20",
    "code": "002038"
  },
  {
    "title": "生物疫苗概念行情向好 双鹭药业涨逾3%",
    "href": "http://stock.jrj.com.cn/invest/2012/07/12111713773598.shtml",
    "datetime": "2012-07-12 11:17:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：未来增长的趋势仍将延续 “推荐”评级",
    "href": "http://stock.jrj.com.cn/hotstock/2012/05/25070213259749.shtml",
    "datetime": "2012-05-25 07:02:06",
    "code": "002038"
  },
  {
    "title": "生物制药涨幅居前 东北制药涨近6%",
    "href": "http://stock.jrj.com.cn/invest/2012/05/03102412981689.shtml",
    "datetime": "2012-05-03 10:24:28",
    "code": "002038"
  },
  {
    "title": "双鹭药业:乙肝疫苗项目上市还需3－5年时间",
    "href": "http://stock.jrj.com.cn/2012/05/02165612973005.shtml",
    "datetime": "2012-05-02 16:56:22",
    "code": "002038"
  },
  {
    "title": "双鹭药业对控股子公司增资",
    "href": "http://stock.jrj.com.cn/2012/02/10025012211956.shtml",
    "datetime": "2012-02-10 02:50:37",
    "code": "002038"
  },
  {
    "title": "双鹭药业拟2520万增资控股子公司",
    "href": "http://stock.jrj.com.cn/2012/02/09172512209385.shtml",
    "datetime": "2012-02-09 17:25:05",
    "code": "002038"
  },
  {
    "title": "双鹭药业：基因工程药物行业龙头",
    "href": "http://stock.jrj.com.cn/hotstock/2012/01/11165412029572.shtml",
    "datetime": "2012-01-11 16:54:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：基因工程药物行业龙头 “推荐”评级",
    "href": "http://stock.jrj.com.cn/hotstock/2012/01/10045012010801.shtml",
    "datetime": "2012-01-10 04:50:32",
    "code": "002038"
  },
  {
    "title": "双鹭药业：加强在糖尿病领域的研发实力",
    "href": "http://stock.jrj.com.cn/hotstock/2011/12/19115011864291.shtml",
    "datetime": "2011-12-19 11:50:59",
    "code": "002038"
  },
  {
    "title": "双鹭药业：北京市场将成增长主力",
    "href": "http://stock.jrj.com.cn/hotstock/2011/12/07105611743729.shtml",
    "datetime": "2011-12-07 10:56:09",
    "code": "002038"
  },
  {
    "title": "国信证券：双鹭药业拓展血制品及疫苗领域",
    "href": "http://stock.jrj.com.cn/hotstock/2011/12/01140911699997.shtml",
    "datetime": "2011-12-01 14:09:24",
    "code": "002038"
  },
  {
    "title": "双鹭药业：业务发展多元化 维持推荐评级",
    "href": "http://stock.jrj.com.cn/hotstock/2011/10/20221611352626.shtml",
    "datetime": "2011-10-20 22:16:14",
    "code": "002038"
  },
  {
    "title": "慧眼+坚守 牛散猎杀超级牛股之路",
    "href": "http://stock.jrj.com.cn/hotstock/2011/10/13141311279885.shtml",
    "datetime": "2011-10-13 14:13:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业:投资加拿大疫苗企业是双赢项目",
    "href": "http://stock.jrj.com.cn/2011/08/16175510756131.shtml",
    "datetime": "2011-08-16 17:55:36",
    "code": "002038"
  },
  {
    "title": "双鹭药业抢卖股权粉饰业绩 有意“先斩后奏”",
    "href": "http://stock.jrj.com.cn/2011/08/03111510621557.shtml",
    "datetime": "2011-08-03 11:15:38",
    "code": "002038"
  },
  {
    "title": "双鹭药业有意“先斩后奏”抢卖股权粉饰业绩",
    "href": "http://stock.jrj.com.cn/sme/2011/08/03043310615434.shtml",
    "datetime": "2011-08-03 04:33:51",
    "code": "002038"
  },
  {
    "title": "双鹭药业1-9月净利预增110%-140%",
    "href": "http://stock.jrj.com.cn/2011/07/30081810586499.shtml",
    "datetime": "2011-07-30 08:18:31",
    "code": "002038"
  },
  {
    "title": "双鹭药业上半年净利润增159%",
    "href": "http://stock.jrj.com.cn/2011/07/30081810586497.shtml",
    "datetime": "2011-07-30 08:18:18",
    "code": "002038"
  },
  {
    "title": "业绩预增近半来靠投资收益 双鹭药业遭机构狂卖3.1亿",
    "href": "http://stock.jrj.com.cn/2011/07/14090610443304.shtml",
    "datetime": "2011-07-14 09:06:06",
    "code": "002038"
  },
  {
    "title": "ST新材3日吸金逾亿元 机构“狠砸”双鹭药业",
    "href": "http://stock.jrj.com.cn/hotstock/2011/07/14034310441464.shtml",
    "datetime": "2011-07-14 03:43:47",
    "code": "002038"
  },
  {
    "title": "双鹭药业：维持买入投资评级 目标价49.6元",
    "href": "http://stock.jrj.com.cn/hotstock/2011/06/27104810302271.shtml",
    "datetime": "2011-06-27 10:48:33",
    "code": "002038"
  },
  {
    "title": "双鹭药业：新老产品齐发力长期看好",
    "href": "http://stock.jrj.com.cn/hotstock/2011/06/13101010184839.shtml",
    "datetime": "2011-06-13 10:10:09",
    "code": "002038"
  },
  {
    "title": "大股东减持埋伏笔 双鹭药业董事长借股权激励“上位”",
    "href": "http://stock.jrj.com.cn/2011/05/1809179993244.shtml",
    "datetime": "2011-05-18 09:17:19",
    "code": "002038"
  },
  {
    "title": "双鹭药业：目标价49.6元 买入的投资评级",
    "href": "http://stock.jrj.com.cn/hotstock/2011/05/1721269989841.shtml",
    "datetime": "2011-05-17 21:26:23",
    "code": "002038"
  },
  {
    "title": "双鹭药业：业绩增长重回上升通道 强烈推荐",
    "href": "http://stock.jrj.com.cn/hotstock/2011/05/1711309985289.shtml",
    "datetime": "2011-05-17 11:30:25",
    "code": "002038"
  },
  {
    "title": "医疗保健：一季度经营保持良好态势",
    "href": "http://stock.jrj.com.cn/2011/04/1609069748327.shtml",
    "datetime": "2011-04-16 09:06:36",
    "code": "002038"
  },
  {
    "title": "弱势股点评",
    "href": "http://stock.jrj.com.cn/hotstock/2011/02/1904569234791.shtml",
    "datetime": "2011-02-19 04:56:35",
    "code": "002038"
  },
  {
    "title": "双鹭药业：主导品种新进多省医保",
    "href": "http://stock.jrj.com.cn/hotstock/2010/10/2209508390432.shtml",
    "datetime": "2010-10-22 09:50:09",
    "code": "002038"
  },
  {
    "title": "双鹭药业：董事长放弃四期行权 终出手",
    "href": "http://stock.jrj.com.cn/2010/10/2105058379143.shtml",
    "datetime": "2010-10-21 05:05:58",
    "code": "002038"
  },
  {
    "title": "双鹭药业：业绩增长暂时放缓",
    "href": "http://stock.jrj.com.cn/2010/10/1507088338527.shtml",
    "datetime": "2010-10-15 07:08:55",
    "code": "002038"
  },
  {
    "title": "双鹭药业：董事长违规买卖股票",
    "href": "http://stock.jrj.com.cn/2010/07/2704477818123.shtml",
    "datetime": "2010-07-27 04:47:49",
    "code": "002038"
  },
  {
    "title": "双鹭药业：肝病肿瘤生物制药龙头 推荐",
    "href": "http://stock.jrj.com.cn/hotstock/2010/06/1715337631756.shtml",
    "datetime": "2010-06-17 15:33:00",
    "code": "002038"
  },
  {
    "title": "双鹭药业：肝病和肿瘤制药龙头 推荐",
    "href": "http://stock.jrj.com.cn/hotstock/2010/06/1707097628273.shtml",
    "datetime": "2010-06-17 07:09:00",
    "code": "002038"
  },
  {
    "title": "最新个股预测点评升降一览（1.29）",
    "href": "http://stock.jrj.com.cn/hotstock/2010/01/2910536895363.shtml",
    "datetime": "2010-01-29 10:53:09",
    "code": "002038"
  },
  {
    "title": "双鹭药业技术员补行权 浮盈超400万",
    "href": "http://stock.jrj.com.cn/sme/2010/01/0607256755811.shtml",
    "datetime": "2010-01-06 07:25:01",
    "code": "002038"
  }
]